Following last weekend's ASCO meeting in Chicago, UBS confirms its sell advice on the stock with a target price of 11,300 pence, representing a potential downside of -8%.

' AstraZeneca held an investor event to highlight some of the results that changed the practice presented for their assets at ASCO this year ' says UBS.

' These include the results of: 1) the LAURA study of Tagrisso in the treatment of stage III unresectable non-small cell lung cancer mutated in the EGFR receptor, and 2) the LAURA study in the treatment of stage III unresectable non-small cell lung cancer ' announces the analyst firm.

AstraZeneca reports that positive results from a phase III trial showed that Imfinzi (durvalumab) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with limited-stage small-cell lung cancer (LS-SCLC) after standard chemoradiotherapy.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.